Basic and diluted net loss per common
share before cumulative effect of
change in accounting principle $(0.04) $(0.03) $(0.05) $(0.13)
Cumulative effect per share of change
in accounting principle $- $- $- $0.01
Basic and diluted net loss per common
share after cumulative effect of
change in accounting principle $(0.04) $(0.03) $(0.05) $(0.12)
Weighted-average shares used in
computing basic net loss per
common share 134,553 132,026 134,372 131,805
Reconciliation of Non-GAAP Proforma
Results to GAAP
Net loss after cumulative effect of
change in accounting principle $(5,518) $(3,872) $(7,246) $(15,430)
Adjustments for certain non-cash
items:
Cumulative effect of change in
accounting principle - - - (2,242)
Contingent Value Rights
valuation adjustment (72) - (72) -
Convertible debt valuation adjustment (66) (4,463) (4,802) (408)
Non-GAAP Proforma net loss (5,656) (8,335) (12,120) (18,080)
Non-GAAP Proforma net loss per common
share, basic $(0.04) $(0.06) $(0.09) $(0.14)
Management believes that this Non-GAAP proforma financial data
supplements the Company's GAAP financial statements by providing investors
with additional information which allows them to have a clearer picture of
the Company's operations, financial performance and the comparability of
the Company's operating results from period to period as they exclude the
effects of revaluation of the Company's convertible debt that management
believes are not indicative of the Company's ongoing operations. The
presentation of this additional information is not meant to be considered
in isolation or as a substitute
'/>"/>
| SOURCE Monogram Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved |